CI Investments Inc. Acquires 9,725 Shares of Abbott Laboratories $ABT

CI Investments Inc. raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 8.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 130,127 shares of the healthcare product maker’s stock after acquiring an additional 9,725 shares during the period. CI Investments Inc.’s holdings in Abbott Laboratories were worth $13,360,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the 4th quarter worth $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at about $26,000. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Evercore decreased their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Raymond James Financial lowered their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $100.69 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company’s fifty day moving average price is $90.92 and its 200-day moving average price is $101.48. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market capitalization of $175.38 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.93 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.51 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.